Table 1.
Demographic and clinicopathological characteristics of patients with extrahepatic bile duct cancer
| Characteristic | Patients (n = 687) |
|---|---|
| Age* | 65.8 (9.0) |
| Sex (M : F) | 488 : 199 |
| BMI* | 23.2 (2.9) |
| CEA (μg/l)† | 1.8 (1.2–2.9) |
| CEA >5 μg/l | 62 (9.0) |
| CA19-9 (kU/l)† | 47.0 (17.2–140.9) |
| CA19-9 >37 kU/l | 386 (56.2) |
| Total bilirubin (µmol/l)† | 1.6 (0.9–3.5) |
| Total bilirubin >51.3 µmol/l | 197 (28.7) |
| Preoperative biliary drainage | |
| ERBD | 345 (50.2) |
| PTBD | 239 (34.8) |
| ENBD | 107 (15.6) |
| PTGBD | 13 (1.9) |
| Operation | |
| Whipple, PPPD | 618 (90.0) |
| Hilar resection | 15 (2.2) |
| HPD | 4 (0.6) |
| Total | 3 (0.4) |
| Bypass | 28 (4.1) |
| Others | 19 (2.8) |
| T stage | |
| 0, 1 | 92 (13.4) |
| 2 | 206 (30.0) |
| 3 | 339 (49.3) |
| 4 | 11 (1.6) |
| N stage | |
| 0 | 427 (62.2) |
| 1 | 199 (29.0) |
| 2 | 19 (2.8) |
Values in parentheses are percentages unless indicated otherwise; *values are indicated mean (SD), †values are indicated median (IQR). CA19–9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; HPD, hepatopancreatoduodenectomy; ENBD, endoscopic nasobiliary drainage; ERBD, endoscopic retrograde biliary drainage; PPPD, pylorus-preserving pancreatoduodenectomy; PTBD, percutaneous transhepatic biliary drainage; PTGBD, percutaneous transhepatic gallbladder drainage.